Recent News

By Region: North America

Ricin And The Risk Of Bioterror: Are We Prepared?

(Forbes) The ghastly bombings in Boston followed by envelopes laced with the lethal poison ricin that were sent to the U.S Capitol and the White House, renew fears about our vulnerability to these kinds of terrorist acts. It invites unwelcome memories of 9-11.

Novavax Initiates Animal Testing of H7N9 VLP Vaccine

(GlobalBiodefense) Novavax, Inc. this week announced it has completed purification of a virus-like particle (VLP) vaccine candidate for the emerging H7N9 influenza and has initiated animal immunogenicity and efficacy studies.

Lyme disease vaccine shows promise in clinical trial

(ScienceDaily) The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International Inc., a U.S. based healthcare company, revealed it to be promising and well tolerated.

After hesitating, Kansas House panel OKs bonds for national biodefense lab

(KansasCity) Gov. Sam Brownback’s administration overcame fresh resistance from the Kansas Legislature on Thursday to his proposal for an additional $202 million in bonds to help cover higher construction costs for a national biodefense lab that state officials had pursued aggressively. The Republican-dominated House Appropriations Committee initially delayed a decision on the governor’s proposal for  Read More »

Medicago Produces VLP Vaccine Candidate for Emerging H7N9 Virus

(GlobalBiodefense) Medicago Inc., a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), this week announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China. “To our knowledge, Medicago is the first to produce  Read More »

« First...102030...9495969798...110120130...Last »

Also filed under "North America":